These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39068716)

  • 21. Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system.
    Rosselot C; Li Y; Wang P; Alvarsson A; Beliard K; Lu G; Kang R; Li R; Liu H; Gillespie V; Tzavaras N; Kumar K; DeVita RJ; Stewart AF; Stanley SA; Garcia-Ocaña A
    Sci Transl Med; 2024 Jul; 16(755):eadg3456. PubMed ID: 38985854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
    Weber C; Sipos M; Paczal A; Balint B; Kun V; Foloppe N; Dokurno P; Massey AJ; Walmsley DL; Hubbard RE; Murray J; Benwell K; Edmonds T; Demarles D; Bruno A; Burbridge M; Cruzalegui F; Kotschy A
    J Med Chem; 2021 May; 64(10):6745-6764. PubMed ID: 33975430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
    Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J
    Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DYRK1A inhibitors for disease therapy: Current status and perspectives.
    Liu T; Wang Y; Wang J; Ren C; Chen H; Zhang J
    Eur J Med Chem; 2022 Feb; 229():114062. PubMed ID: 34954592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A.
    Miyazaki Y; Kikuchi M; Umezawa K; Descamps A; Nakamura D; Furuie G; Sumida T; Saito K; Kimura N; Niwa T; Sumida Y; Umehara T; Hosoya T; Kii I
    Eur J Med Chem; 2022 Jan; 227():113948. PubMed ID: 34742017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
    Rüben K; Wurzlbauer A; Walte A; Sippl W; Bracher F; Becker W
    PLoS One; 2015; 10(7):e0132453. PubMed ID: 26192590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition.
    Abdolazimi Y; Zhao Z; Lee S; Xu H; Allegretti P; Horton TM; Yeh B; Moeller HP; Nichols RJ; McCutcheon D; Shalizi A; Smith M; Armstrong NA; Annes JP
    Endocrinology; 2018 Sep; 159(9):3143-3157. PubMed ID: 29514186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD).
    Gehlot P; Pathak R; Kumar S; Choudhary NK; Vyas VK
    Bioorg Med Chem; 2024 Nov; 113():117925. PubMed ID: 39357433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
    Cuny GD; Ulyanova NP; Patnaik D; Liu JF; Lin X; Auerbach K; Ray SS; Xian J; Glicksman MA; Stein RL; Higgins JM
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2015-9. PubMed ID: 22335895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors.
    Bruel A; Bénéteau R; Chabanne M; Lozach O; Le Guevel R; Ravache M; Bénédetti H; Meijer L; Logé C; Robert JM
    Bioorg Med Chem Lett; 2014 Nov; 24(21):5037-40. PubMed ID: 25248682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
    Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
    J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
    Yoon HR; Balupuri A; Choi KE; Kang NS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules.
    Rothweiler U; Stensen W; Brandsdal BO; Isaksson J; Leeson FA; Engh RA; Svendsen JS
    J Med Chem; 2016 Nov; 59(21):9814-9824. PubMed ID: 27736065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.
    Liu YA; Jin Q; Zou Y; Ding Q; Yan S; Wang Z; Hao X; Nguyen B; Zhang X; Pan J; Mo T; Jacobsen K; Lam T; Wu TY; Petrassi HM; Bursulaya B; DiDonato M; Gordon WP; Liu B; Baaten J; Hill R; Nguyen-Tran V; Qiu M; Zhang YQ; Kamireddy A; Espinola S; Deaton L; Ha S; Harb G; Jia Y; Li J; Shen W; Schumacher AM; Colman K; Glynne R; Pan S; McNamara P; Laffitte B; Meeusen S; Molteni V; Loren J
    J Med Chem; 2020 Mar; 63(6):2958-2973. PubMed ID: 32077280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects.
    AlNajjar YT; Gabr M; ElHady AK; Salah M; Wilms G; Abadi AH; Becker W; Abdel-Halim M; Engel M
    Eur J Med Chem; 2022 Jan; 227():113911. PubMed ID: 34710745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of DYRK1A Stimulates Human β-Cell Proliferation.
    Dirice E; Walpita D; Vetere A; Meier BC; Kahraman S; Hu J; Dančík V; Burns SM; Gilbert TJ; Olson DE; Clemons PA; Kulkarni RN; Wagner BK
    Diabetes; 2016 Jun; 65(6):1660-71. PubMed ID: 26953159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors.
    Park A; Hwang J; Lee JY; Heo EJ; Na YJ; Kang S; Jeong KS; Kim KY; Shin SJ; Lee H
    Bioorg Med Chem Lett; 2021 Sep; 47():128226. PubMed ID: 34182093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's Disease.
    Warren HT; Saeger HN; Tombari RJ; Chytil M; Rasmussen K; Olson DE
    J Med Chem; 2024 May; 67(9):6922-6937. PubMed ID: 38648167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation.
    Kumar K; Wang P; A Swartz E; Khamrui S; Secor C; B Lazarus M; Sanchez R; F Stewart A; DeVita RJ
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32340326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
    Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
    J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.